on Immunic AG
Immunic, Inc. to Release Q3 2024 Financial Results and Corporate Update
Immunic, Inc., a biotechnology firm focused on small molecule therapies for chronic inflammatory and autoimmune diseases, will announce its financial results for the third quarter of 2024 on November 7. The company will also present a corporate update via a webcast at 8:00 am ET on the same day. Interested parties can register in advance on the company's website to participate.
Immunic is progressing with its lead program, vidofludimus calcium, which is undergoing clinical trials for various stages of multiple sclerosis and ulcerative colitis. This compound aims to combine neuroprotective, anti-inflammatory, and antiviral effects. The company's other developments include IMU-856 for gastrointestinal diseases and IMU-381 in preclinical testing.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Immunic AG news